効果 | なし |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 73 |
性別 | 男女 |
年齢 | 45-64 |
Supplementation of 1,200mg colostrum (40% immunoglobulins) daily for 24 weeks in HIV infected persons on stable antiretroviral therapy (known to decrease CD4+ lymphocytes) failed to improve the suppressed lymphocytes relative to control. Serum HIV-RNA was also not affected by therapy.
ColoPlus, A New Product Based On Bovine Colostrum, Alleviates HIV-associated Diarrhoea
効果 | 増加 |
試験方法 | コホート法 |
試験期間 | 2-4 週間 |
被験者数 | 30 |
性別 | 男女 |
年齢 | 18-29, 30-44, 45-64 |
In HIV-infected persons with associated diarrhea, a colostrum containing porridge known as ColoPlus (32% colostrum, where each 50g pack contained 2-4g immunoglobulins and is taken twice daily) for four weeks was able to greatly reduce daily bowel movements from 7 down to 1.6, the benefit lasting for an additional two weeks after supplement cessation.
It was noted that CD4+ lymphocytes increased in all persons, to a larger degree in those with less than 200 cells per microliter (experiencing a 94-110% increase) and that fatigue associated with HIV was reduced 81%.
Effect Of A Mixture Of Micronutrients, But Not Of Bovine Colostrum Concentrate, On Immune Function Parameters In Healthy Volunteers: A Randomized Placebo-controlled Study
効果 | なし |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 138 |
性別 | 男女 |
年齢 | 30-44, 45-64, 65+ |
体型 | 平均 |
Supplementation of colostrum (1,200mg, conferring 500mg immunoglobulins) failed to appreciably influence various immune parameters and DTH responsiveness relative to placebo.
Effect Of Bovine Colostrum-based Food Supplement In The Treatment Of HIV-associated Diarrhea In Northern Uganda: A Randomized Controlled Trial
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 2-4 週間 |
被験者数 | 97 |
性別 | 男女 |
年齢 | 18-29, 30-44, 45-64 |
体型 | 平均, Underweight |
50g of a colostrum containing porridge (twice daily) for four weeks to persons with HIV-associated diarrhea for four weeks (and followed up for an additional five) significantly reduced stool frequency 79% (58% in controls given standard anti-diarrhea therapy) and increased CD4+ lymphocytes 14% despite a 12% decrease in control. Fatigue was reported to be reduced by 85% relative to baseline, greater than the 43% reduction seen with placebo.